Enhanced external counterpulsation for management of symptoms associated with long COVID

American Heart Journal Plus

Mohanakrishnan Sathyamoorthy¹  John Spertus²  Monica Verduzco-Gutierrez³  Swathi Varanasi⁴  Sachin Shah⁴  Robyn Ward⁵ 

[1] Department of Internal Medicine, Texas Christian University and University of North Texas Health Science Center School of Medicine, Fort Worth, TX, USA;Department of Internal Medicine, University of Missouri–Kansas City School of Medicine, Kansas City, MO, USA;Department of Physical Medicine and Rehabilitation, Joe R. and Teresa Lozano Long School of Medicine, San Antonio, TX, USA;Flow Therapy, Fort Worth, TX, USA;Texas Cardiovascular Institute, Fort Worth, TX, USA;

关键词: Long COVID;    EECP;    COVID-19;    PASC;    Long Haul Syndrome;   

DOI  :  

来源: DOAJ

【 摘 要 】

Study objective: Enhanced external counterpulsation (EECP) as a possible therapy for Long COVID. Design: Retrospective analysis of a contemporary, consecutive patient cohort. Setting: 7 outpatient treatment centers. Participants: Long COVID patients. Intervention: 15–35 EECP treatments. Main outcome measures: The change from baseline in 1) Patient Reported Outcome Measurement Information System (PROMIS) Fatigue; 2) Seattle Angina Questionnaire (SAQ); 3) Duke Activity Status Index (DASI); 4) 6-Minute Walk Test (6MWT); 5) Canadian Cardiovascular Society (CCS) Angina Grade; 6) Rose Dyspnea Scale (RDS); and 7) Patient Health Questionnaire (PHQ-9). Results: Compared to baseline, the PROMIS Fatigue, SAQ, DASI, and 6MWT improved by 4.63 ± 3.42 (p < 0.001), 21.44 ± 16.54 (p < 0.001), 18.08 ± 13.82 (p < 0.001), and 200.00 ± 180.14 (p = 0.002), respectively. CCS and RDS improved in 63% and 44% of patients, respectively. All patients unable to work prior to EECP were able to return post-therapy. Conclusions and relevance: EECP significantly improved validated fatigue and cardiovascular-related markers in patients with Long COVID.

【 授权许可】

Unknown